Daewoong Pharmaceutical announced on the 9th that its botulinum toxin "Nabota" obtained an item license in Singapore on the 20th of last month. The acquisition of Singapore permits was the first of its kind among domestic botulinum drugs, and Nabota has increased the number of licensed countries worldwide to 62.

Nabota 100 units are approved by the Singapore Health and Science Agency (HSA). Daewoong Pharmaceutical applied for an item license in September 2021. Daewoong Pharmaceutical plans to release Nabota in Singapore in the third quarter of this year. Hypens Pharma Pte Ltd is in charge of local distribution and sales. Hypens Pharma is a subsidiary of the SGX-listed Hypens Group.

Compar